Application of Kauri extract in the preparation of products for treating acute lung injury caused by sepsis

The preparation of drugs using Araucarone (AO) from Kauri extract has solved the treatment challenge of acute lung injury in sepsis, achieving effective inhibition of acute lung injury in sepsis and improving survival rate.

CN119015328BActive Publication Date: 2026-11-17PEKING UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310584206.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-23
Publication Date
2026-11-17
Estimated Expiration
2043-05-23

AI Technical Summary

Technical Problem

There are currently no reports on the effects of Kauri or its monomeric components on sepsis-related effects, especially regarding the lack of effective drugs for the prevention and treatment of acute lung injury in sepsis.

Method used

Araucarone (AO) from Kauri extract was used as the active ingredient to prepare a drug through ethanol-water extraction. The drug inhibited acute lung injury in sepsis, including inhibiting the increase in lung weight index, alveolar interstitial remodeling and inflammatory cell infiltration, regulating macrophage M1 polarization and inflammatory factor expression, and inhibiting oxidative stress and aerobic glycolysis of M1 polarized macrophages.

Benefits of technology

It significantly inhibits LPS-induced acute lung injury in mice with sepsis, reduces the expression of inflammatory factors, and improves survival rate, providing a safe, low-toxicity, and readily available drug solution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure BDA0004242681010000021
    Figure BDA0004242681010000021
  • Figure BDA0004242681010000061
    Figure BDA0004242681010000061
Patent Text Reader

Abstract

This invention discloses the application of Agathis dammara extract in the preparation of products for treating acute sepsis-induced lung injury, belonging to the pharmaceutical field. This invention discloses a novel pharmaceutical use of Agathis dammara extract (AD) and its monomer, araaucarone (AO). The novel use is the application of Agathis dammara extract and araaucarone in treating acute sepsis-induced lung injury. This invention uses a clinically relevant acute sepsis-induced lung injury model: an LPS-induced mouse model of acute sepsis-induced lung injury; experiments have demonstrated that gavage administration of Agathis dammara extract or araaucarone significantly inhibits LPS-induced acute sepsis-induced lung injury in mice, and can be used for the prevention and treatment of acute sepsis-induced lung injury.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the pharmaceutical field, specifically to the application of Kauri extract in the preparation of products for treating acute lung injury caused by sepsis. Background Technology

[0002] Kauri (Latin name *Agathis dammara*) is a tree belonging to the phylum Gymnosperms, class Pinopsida, order Pinales, family Araucariaceae, and genus *Agathis*. It is mainly distributed in tropical Asia and has been introduced and cultivated in Xiamen and Fuzhou, my country. Its leaves contain volatile oils primarily composed of terpenoids, with β-piperine being the main component. Other components include alkanes, alcohols, ketones, and small amounts of aldehydes, ethers, and esters. It has important applications in medicine, fragrances, and cosmetics, and is also significant in phytochemical taxonomy. The pharmacological effects of Kauri can be broadly categorized as follows: antitumor, antibacterial, anti-inflammatory, sedative, and antiasthmatic.

[0003] Sepsis is one of the representative acute systemic inflammatory diseases. Imbalance in the inflammatory response is the most critical pathological basis of sepsis and persists throughout its entire course. The host's acute response to pathogens triggers macrophage M1 polarization, leading to the engulfment of pathogens and the production of large amounts of pro-inflammatory factors, ultimately triggering a cytokine storm. An uncontrolled cytokine storm can lead to shock, multiple organ failure, and death. Inhibiting macrophage M1 polarization during the acute inflammatory phase of sepsis can suppress the release of inflammatory factors, reduce tissue damage, and improve survival rates. Therefore, regulating macrophage polarization homeostasis is of great significance for reducing tissue damage and mortality in sepsis patients.

[0004] There are currently no reports on the effects of Kauri or its monomeric components on sepsis. Summary of the Invention

[0005] The purpose of this invention is to provide a new use for kauri extract.

[0006] The novel use of Kauri extract provided by this invention is its application in the preparation of products for the prevention and / or treatment of acute lung injury in sepsis.

[0007] In the above application, the sepsis-induced acute lung injury is sepsis-induced acute lung injury caused by bacterial infection; specifically, the bacteria are Gram-negative bacteria.

[0008] More specifically, the sepsis-induced acute lung injury is LPS-induced sepsis-induced acute lung injury in mice.

[0009] The present invention also provides the use of kauri extract in at least one of the following:

[0010] 1) Application in the preparation of products that inhibit acute lung injury in sepsis; specifically, the inhibition of acute lung injury in sepsis is manifested in inhibiting the increase in lung weight index, alveolar interstitial remodeling and inflammatory cell infiltration;

[0011] 2) Application in the preparation of products that inhibit inflammatory responses in lung tissue; specifically, application in the preparation of products that inhibit the expression of inflammatory factors in septic lung tissue; wherein the inflammatory factors may be at least one of IL-6, TNF-α, IL-18 and IL-1β;

[0012] 3) Application in the preparation of products that inhibit macrophage M1 polarization; specifically, the markers of macrophage M1 polarization are CD86, CD80, and iNOS;

[0013] 4) Application in the preparation of products that inhibit the production of macrophage inflammatory factors; specifically, the macrophage inflammatory factors are IL-6, MCP-1, and TNF-α;

[0014] 5) Application in the preparation of products that inhibit oxidative stress in M1 polarized macrophages; specifically, the antioxidant stress protein in the M1 polarized macrophages is HO-1 protein;

[0015] 6) Application in the preparation of products that inhibit aerobic glycolysis of M1 polarized macrophages; specifically, the key enzyme in aerobic glycolysis of M1 polarized macrophages is hexokinase 2 (HK2), which inhibits glucose consumption and lactate production.

[0016] In the above applications, the active ingredient of the kauri extract includes Araucarone (AO), whose structural formula is shown below:

[0017]

[0018] In the above applications, the Kauri extract is an ethanol-water aqueous solution extract of Kauri.

[0019] Specifically, the volume fraction of ethanol in the ethanol-water solution is 60% to 100%; more specifically, it can be 95%.

[0020] The Kauri extract described in this invention can be prepared according to existing publicly available methods.

[0021] The following method can be used for preparation: dry and pulverize the rhizomes of Kauri, soak them in an aqueous ethanol solution, heat to a slight boiling state, reflux for extraction, collect the extract, concentrate and dry it to obtain the Kauri extract.

[0022] The soaking time can be 1 hour; the reflux extraction is performed at least once, preferably three times; the reflux extraction time for each extraction is 1 to 2 hours.

[0023] In the above applications, the product is a drug or a drug preparation.

[0024] The drug can be introduced into the body, such as into muscles, intradermal, subcutaneous, venous, or mucosal tissues, through injection, oral administration, spraying, penetration, absorption, or physical or chemical means; or it can be introduced into the body after being mixed with or encapsulated by other substances.

[0025] When necessary, one or more pharmaceutically acceptable carriers may be added to the above-mentioned drugs to form a pharmaceutical formulation. These carriers include diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption enhancers, surfactants, adsorbents, lubricants, etc., commonly used in the pharmaceutical field.

[0026] The drug can be formulated into various forms such as injections, suspensions, powders, tablets, and granules. All of these dosage forms can be prepared using conventional methods in the pharmaceutical field.

[0027] This invention employs a clinically relevant acute lung injury model of sepsis: LPS-induced acute lung injury in mice. Experiments demonstrated that oral administration of Kauri extract significantly inhibited the occurrence and progression of LPS-induced acute lung injury in mice. Furthermore, it was shown that the active ingredient in Kauri extract includes Araucarone (AO).

[0028] The drug for treating acute lung injury caused by sepsis provided by this invention is safe, low in toxicity, and has strong pharmacological effects. Its raw materials are abundant and can be extracted from the Kauri plant. This invention provides a new drug source for the prevention, protection, treatment, and research of acute lung injury caused by sepsis, and it is easy to promote and apply, capable of generating significant social and economic benefits in a short period of time. Attached Figure Description

[0029] Figure 1 Kauri extract (AD) inhibited LPS-induced M1 polarization, inflammatory cytokine production, and oxidative stress in RAW264.7 macrophages;

[0030] Figure 1 In this context, 'a' represents the safety of AD cells as determined by the MTT assay. Figure 1 In the text, bd represents AD's inhibition of increased mRNA expression levels of inflammatory factors IL-6, TNF-α, and MCP-1; Figure 1 In the example eg, AD inhibits the increase in mRNA expression levels of M1 polarized macrophage markers CD86, CD80, and iNOS; Figure 1In the text, hi represents the upregulation of protein expression of the M1 polarization marker iNOS by AD. Figure 1 In AD, jl represents the upregulation of protein expression of the inflammatory factors caspase 1 and IL-18. Figure 1 In the figure, m represents the DCFHDA probe detection, and AD inhibits LPS-induced increase in oxidative stress levels in RAW264.7 macrophages.

[0031] Figure 2 Kauri extract (AD) inhibits LPS-induced M1 polarization and inflammatory factor production in bone marrow-derived macrophages (BMDM);

[0032] Figure 2 a, b, f, and g in the figure represent AD inhibiting the increase in mRNA expression levels of inflammatory factors TNF-α, MCP-1, IL-6, and IL-18 in BMDM, respectively. Figure 2 In this context, ce represents the increased mRNA expression levels of AD-mediated inhibition of M1-polarized macrophage markers iNOS, CD86, and CD80. Figure 2 In the equation, i and h represent the upregulation of protein expression of the M1 polarization marker iNOS, which is inhibited by AD. Figure 2 In the equation, jk represents AD inhibition of the upregulation of the M1 polarization marker CD86;

[0033] Figure 2 The concentration of AD in ah was 25 μg / mL; Figure 2 In the j and k, AD indicates AD treatment at 25 μg / mL; LPS indicates LPS treatment at 100 ng / mL; 0, 5, and 25 indicate treatment with 100 ng / mL LPS while simultaneously receiving AD treatment at different concentrations (μg / mL).

[0034] Figure 3 Kauri extract (AD) inhibits the expression of HK2 gene, a key enzyme in the glycolysis pathway, in RAW264.7 cells;

[0035] Figure 3 In the text, ab represents AD inhibition of increased glucose consumption and lactate production after 12 hours of LPS treatment; Figure 3 cd in the figure represents the inhibition of increased glucose consumption and lactate production after 24 hours of LPS treatment by AD. Figure 3 In the figure, 'e' represents the AD inhibition of LPS-induced increase in the mRNA expression level of hexokinase (HK2) in RAW264.7 cells.

[0036] Figure 4 Kauri extract (AD) inhibits glycolysis and the expression of HK2 gene, a key enzyme in the glycolysis pathway, in BMDM cells;

[0037] Figure 4In this context, ab represents AD inhibiting the increase in glucose consumption and lactate production after 12 hours of LPS treatment; Figure 4 In the figure, c represents AD inhibition of LPS-induced increase in the mRNA expression level of hexokinase (HK2) in BMDM.

[0038] Figure 5 Kauri extract (AD) inhibited acute lung injury, M1 polarized macrophage infiltration in lung tissue, and production of inflammatory factors in lung tissue in septic mice;

[0039] Figure 5 In the figure, ab represents the effect of 100 mg / kg AD on the survival rate of mice with sepsis induced by intraperitoneal injection of 45 mg / kg LPS. Here, a is a schematic diagram of the mouse survival experiment; b is a statistical graph of mouse survival rate. Figure 5 In the figure, ck represents the inhibitory effect of 100 mg / kg AD administered by gavage on acute lung injury induced by intraperitoneal injection of 20 mg / kg LPS in septic mice. c is a schematic diagram of the experimental procedure; d represents the inhibition of LPS-induced increase in lung weight index in septic mice by AD; ef represents the inhibition of increased mRNA expression levels of M1 polarization markers CD80 and CD86 in lung tissue of septic mice by AD; gj represents the inhibition of increased mRNA expression levels of inflammatory factors IL-6, IL-18, TNF-α, and IL-1β in lung tissue by AD; and k represents the inhibition of LPS-induced lung tissue injury in mice (HE staining of lung tissue sections), including inhibition of alveolar septal thickening and inhibition of cell infiltration.

[0040] Figure 6 Araucaria zeolite (AO) inhibits LPS-induced M1 polarization, inflammatory cytokine production, and oxidative stress in RAW264.7 macrophages;

[0041] Figure 6 In the figure, 'a' represents the effect of different concentrations of AO on cell viability as detected by the MTT assay, and LPS is 100 ng / mL. Figure 6 The bd values ​​in the text represent the inhibition of LPS (100 ng / mL)-induced increases in mRNA expression levels of cellular inflammatory factors MCP-1, IL-6, and TNF-α by 25 μM AO (with 25 μg / mL AD as a control). Figure 6 The e in the study was that 25 μM AO (with 25 μg / mL AD as the control) inhibited the increase in mRNA expression level of the M1 polarized macrophage marker iNOS induced by LPS (100 ng / mL); Figure 6 fg in the figure represents the inhibition of the increase in mRNA expression levels of M1 polarized macrophage markers CD80 and CD86 induced by different concentrations of AO (μM); Figure 6The hj in the study was 25 μM AO (with 25 μg / mL AD as the control) which inhibited the downregulation of the expression level of the antioxidant protein HO-1 and the upregulation of the expression level of the inflammatory factor IL-18 induced by LPS (100 ng / mL).

[0042] Figure 7 Araucaria zeolite (AO) inhibits acute lung injury, M1 polarized macrophage infiltration in lung tissue, and production of inflammatory factors in lung tissue in septic mice;

[0043] Figure 7 In the figure, ah represents the inhibitory effect of 100 mg / kg AO administered by gavage on acute lung injury induced by intraperitoneal injection of 20 mg / kg LPS in septic mice. Specifically, a is a schematic diagram of the experimental procedure; b shows the inhibition of AO on the increase in lung weight index induced by LPS in septic mice; cd shows the inhibition of AO on the increase in mRNA expression levels of M1 polarization markers CD80 and CD86 in lung tissue of LPS-induced septic mice; eg shows the inhibition of AO on the increase in mRNA expression levels of inflammatory factors IL-6, TNF-α, and IL-1β in lung tissue of septic mice; and h shows HE staining of lung tissue sections from septic mice, indicating that AO can inhibit LPS-induced lung tissue injury in septic mice, including inhibiting alveolar septal thickening and inflammatory cell infiltration. Detailed Implementation

[0044] The present invention will be further described in detail below with reference to specific embodiments. The embodiments given are only for illustrating the present invention and are not intended to limit the scope of the present invention.

[0045] Unless otherwise specified, the experimental methods described in the following examples are conventional methods.

[0046] Unless otherwise specified, all materials and reagents used in the following examples are commercially available.

[0047] All percentages mentioned in the following examples are mass percentages, unless otherwise stated.

[0048] The lipopolysaccharide (LPS) used in the following examples was purchased from Sigma Aldrich, catalog number L2880.

[0049] In the following examples, the solvent for AD or AO is 0.5% sodium carboxymethyl cellulose, and the solvent for sodium carboxymethyl cellulose is distilled water;

[0050] The solvent for LPS is physiological saline.

[0051] Example 1: Preparation of Kauri extract (AD) and its monomers

[0052] 1. Preparation of Kauri extract

[0053] 367g of dried and pulverized Kauri root powder was placed in a 3.0L round-bottom flask, and 2.5L of 95% (v / v) ethanol was added. After soaking for 1 hour, the mixture was heated to a gentle boil and refluxed for 2 hours. The extract was filtered while hot. The residue was then extracted twice more with 2.0L of 95% (v / v) ethanol under reflux, each time for 1.5 hours. The filtrates were combined, concentrated using a rotary evaporator, vacuum dried, and weighed to obtain 105.3g of Kauri extract (extraction rate: 28.7%).

[0054] 2. Preparation of monomers

[0055] Take the kauri extract (100.0g) prepared above, add 1.0L of water to suspend it, and extract it with dichloromethane. The amount of extractant used each time is 1.0L, and the extraction is performed 3 times. Combine the extracts to obtain 34.0g of dichloromethane layer extract.

[0056] The dichloromethane extract (34 g) was mixed with silica gel (Qingdao Ocean Chemical, 300-400 mesh column chromatography silica gel; catalog number: 2.003447F6) at a mass ratio of 1:2 and loaded onto a 3.3 L silica gel column for purification. The elution was performed sequentially with dichloromethane, dichloromethane / methanol gradients at the following ratios: pure dichloromethane, dichloromethane / methanol 50:1, 20:1, 10:1, 5:1, 2:1, 1:1, and pure methanol (v / v), 6 L for each gradient. Based on the thin-layer chromatography results, fractions with similar characteristics were combined, resulting in 22 fractions. Fraction 1 (4.4 g) was mixed into 7.0 g of silica gel and loaded onto a silica gel column (column volume 261 mL). Elution was performed with petroleum ether and petroleum ether / ethyl acetate, using elution gradients of petroleum ether (600 mL), petroleum ether / ethyl acetate (v / v) 30:1, 20:1, 10:1, 5:1, 4:1, 3:1, 2:1, and 1:1 (400 mL for each gradient). Fractions of the same type were combined by thin-layer chromatography to obtain nine subfractions (A–I). Subfraction H was recrystallized at room temperature to yield the monomer compound.

[0057] The purity of the monomer was determined by HPLC, and the purity was >95%. The detection conditions were as follows:

[0058] Mobile phase: 100% acetonitrile; flow rate: 1 mL / min; column: Welch Ultimate XB-C18 (250 mm × 4.6 mm id, 5 μm); column temperature: 40 ℃; detection wavelength: 254 nm, 210 nm.

[0059] The structure of the compound was identified using mass spectrometry and nuclear magnetic resonance spectroscopy.

[0060] Compound 1, ESI-MS m / z 301[M+H]+, 1H-NMR (CDCl3, 600MHz) δH: 5.50 (1H, m), 4.40 (2H, s), 3.26 (1H, br.s), 2.70 (1H, td, J=14.6, 5.3Hz ),2.29(1H,br.d,J=11.5Hz),2.27(1H,dt,J=14.7,3.8Hz),2.14(1H,m),2.12(1H,m),2.10(1H,m),1.94(1H,m ),1.75(1H,br.dd,J=6.2,3.1Hz),1.73(1H,m),1.68(1H,m),1.63(1H,td,J=12.8,3.7Hz),1.56(1H,dd,J=12. 2,4.1Hz),1.50(1H,td,J=13.9,4.0Hz),1.45(1H,qd,J=12.5,4.2Hz),1.14(3H,s),1.10(6H,s),1.07(3H,s);

[0061] 13C-NMR (CDCl3, 151MHz) δC: 216.5, 214.9, 133.3, 123.3, 64.1, 51.5, 50.7, 4 7.4,45.9,41.7,38.0,35.3,34.6,32.5,25.6,23.9,22.6,19.5,18.9,14.8.

[0062] The compound was named AO (Araucarone), and its structural formula is as follows:

[0063]

[0064] Example 2: Pharmacodynamic test of kauri extract

[0065] 1. Experimental Materials

[0066] 1.1 Laboratory Animals

[0067] The mice used in the experiment were 8-week-old male C57BL / 6J mice with an average weight of 20-25g, purchased from the Laboratory Animal Center of Peking University School of Medicine. The laboratory animal care principles were followed (NIH Publication No. 85-23, Revised 1996), and the experimental protocol was approved by the Animal Ethics Committee of Peking University School of Medicine (Approval No.: LA2021045): all mice were housed under 12-hour light-dark cycle conditions and had free access to food and water.

[0068] 1.2 Animal feed

[0069] Animal maintenance feed is a commercially available general feed for rodents.

[0070] 2. In vivo experimental methods

[0071] 2.1 LPS-induced acute lung injury model of sepsis in mice

[0072] Eight-week-old male C57BL / 6J mice were used to induce acute lung injury due to sepsis by intraperitoneal injection of 20 mg / kg LPS (LPS was prepared into a 2 mg / mL solution with physiological saline). Tissue samples were collected 24 hours later. The control group was injected intraperitoneally with the same amount of physiological saline.

[0073] Eight-week-old male C57BL / 6J mice were intraperitoneally injected with 45 mg / kg LPS (LPS was prepared into a 5 mg / mL solution with physiological saline) to induce sepsis, and the survival rate of the mice was observed. The control group was injected intraperitoneally with the same amount of physiological saline.

[0074] 2.2 Pharmacological effects of Kauri extract against acute lung injury caused by sepsis

[0075] (1) Drug efficacy experiment

[0076] Eight-week-old male C57BL / 6J mice were randomly divided into a control group (n=6), an LPS modeling group (n=6), an LPS modeling group simultaneously administered with Kauri extract (AD 100 mg / kg / day, n=6), or an LPS modeling group simultaneously administered with monosodium hydroxylapatite (AO 100 mg / kg / day, n=6). Mice were pre-gavaged for 5 days. The control and LPS modeling groups were administered the same volume of solvent (0.5% sodium carboxymethyl cellulose) daily via gavage. The LPS modeling group simultaneously administered with Kauri extract and the LPS modeling group simultaneously administered with monosodium hydroxylapatite were administered AD and AO at 100 mg / kg via gavage daily (AD or AO was prepared as a 12.5 mg / mL suspension). Two hours after gavage on day 5, the control group received an intraperitoneal injection of an equal volume of physiological saline; the LPS modeling group, the LPS modeling group simultaneously administered with Kauri extract, and the LPS modeling group simultaneously administered with monosodium hydroxylapatite were injected intraperitoneally with 20 mg / kg LPS. Mice were sacrificed 24 hours later, and serum and lung tissue were collected. No further drug treatment was administered after intraperitoneal injection of LPS to establish the model, and this dose of LPS was non-lethal, with a survival rate of 100% within 24 hours.

[0077] (2) Survival rate experiment

[0078] Eight-week-old male C57BL / 6J mice were randomly divided into a control group (n=6), an LPS modeling group (n=6), and a group receiving LPS modeling combined with Kauri extract via gavage (AD 100 mg / kg / day, n=6). For survival observation, mice were pretreated with AD for 5 days. The control and LPS modeling groups were administered the same dose of solvent (0.5% sodium carboxymethyl cellulose) daily via gavage. The LPS modeling combined with Kauri extract group received AD 100 mg / kg daily via gavage. Two hours after administration on day 5, the control group received an intraperitoneal injection of an equal volume of saline; the LPS modeling group and the LPS modeling combined with Kauri extract group received an intraperitoneal injection of 45 mg / kg LPS. Survival time was then observed, and survival rate statistics were plotted. No further drug treatment was administered after LPS modeling. Lung weight index and RNA were not measured in these mice. AD was administered as a 12.5 mg / mL suspension via gavage.

[0079] 2.3 Animal handling

[0080] 2.3.1 Collection of mouse serum

[0081] 24 hours after modeling, before sacrificing the mice, anesthetize them and collect about 800 μL of blood from the inner canthus. Store the blood temporarily at 37°C, centrifuge at 4000 rpm at room temperature for 30 min, collect the supernatant serum, and freeze it at -30°C for later use.

[0082] 2.3.2 Mouse sampling

[0083] Lung tissue sampling: The mice were weighed and their weight recorded. Blood was collected from the inner canthus, and the mice were sacrificed and pinned to a dissecting tray (styrofoam box). The skin and subcutaneous membrane of the mice were incised to expose the internal organs. Lung tissue was harvested, and after vacuuming in cold PBS solution to remove blood, the lung tissue was weighed. Morphological samples were collected from the left lung, fixed in paraformaldehyde, and then transferred to 20% sucrose (w / v). Lung tissue sections were then stained with hematoxylin and eosin (HE) to observe tissue damage. The right lung was cryopreserved at -80°C for later use.

[0084] 2.4 RNA Extraction

[0085] (1) After removing the right lung tissue from the -80℃ freezer, add 1 mL of total RNA extraction reagent (Trizol) per 30 mg of tissue for homogenization and let it stand on ice for 5 min. (For cells, add 1 mL of Trizol directly to the six-well plate, pipette and aspirate into EP tubes).

[0086] (2) Add 200 μL of chloroform, shake vigorously for 30 seconds, and let stand on ice for 3 minutes.

[0087] (3) Centrifuge at 4℃ and 13000rpm for 15min.

[0088] (4) Take the supernatant (500 μL), add 500 μL of pre-cooled isopropanol, mix by inverting for 5 seconds, and let stand on ice for 10 minutes.

[0089] (5) Centrifuge at 4℃ and 13000rpm for 10min.

[0090] (6) Discard the supernatant and add 1 mL of pre-cooled 75% (v / v) ethanol (prepared with DEPC water) to wash the precipitate.

[0091] (7) Centrifuge at 4℃ and 13000rpm for 10min. Wash again and repeat (6)(7).

[0092] (8) Dry RNA at room temperature.

[0093] (9) Dissolve the RNA in an appropriate amount of diethyl pyrocarbonate (DEPC) water and use NanoDrop. TM The concentration and mass were determined using a micro-ultraviolet-visible spectrophotometer. RNA samples were stored at -80°C.

[0094] 2.5 HE staining of lung tissue

[0095] (1) After the frozen slices are dried, wash them with distilled water for 5 min × 3 times.

[0096] (2) Stain with hematoxylin stain for 5 minutes.

[0097] (3) Wash with distilled water, then decompose with 1% hydrochloric acid ethanol (hydrochloric acid / anhydrous ethanol = 1:99, v / v) for a few seconds.

[0098] (4) Rinse with running water, return to blue, until cell nuclei are clearly stained.

[0099] (5) Wash with 95% (v / v) ethanol for 2 min.

[0100] (6) Stain with eosin for 30 min.

[0101] (7) Rinse briefly with distilled water, then rinse with 70% ethanol, 80% ethanol, and 90% ethanol for 30 seconds each, followed by 95% ethanol for 5 minutes and anhydrous ethanol for 5 minutes twice. All the above ethanol concentrations are volume percentages.

[0102] (8) Xylene 10min × 2 times.

[0103] (9) Seal the film with neutral resin, dry it, and take a picture.

[0104] 3. In vitro experimental methods

[0105] 3.1 Extraction of primary mouse bone marrow-derived macrophages

[0106] (1) Prepare 8-week-old C57BL / 6J mice with an average weight of 20-22g.

[0107] (2) The mice were anesthetized and euthanized, and sterile surgical instruments were used throughout the procedure. The skin of the mice was disinfected with 75% (v / v) alcohol. The skin was cut at the base of the hind legs, and the outer skin of the mice was peeled off all the way to the feet to fully expose the muscles.

[0108] (3) Cut off the hind limb and remove the skin with sterile scissors and tweezers.

[0109] (4) Use scissors and tweezers to remove the muscle that is attached to the bone.

[0110] (5) Place the femur and tibia in a culture dish, disinfect with 75% (v / v) alcohol for 1 min, and then wash with PBS.

[0111] (6) After separating bone marrow from mouse tibia and femur, cells were filtered using a 70μm cell sieve to remove cell blocks, bone, hair, etc.

[0112] (7) Centrifuge the collected bone marrow cell suspension. 4℃, 450g, 10min.

[0113] (8) Discard the supernatant, add erythrocyte lysis buffer (0.5 mL / animal), and incubate on ice for 5 min to lyse the erythrocytes. 4℃, 450g, 10 min.

[0114] (9) Discard the supernatant and wash once with Roswell Park Memorial Institute 1640 (RPMI 1640) complete medium. 4°C, 450g, 10min.

[0115] (10) Discard the supernatant, resuspend the cells in 20 mL of preheated complete culture medium, and transfer the cells to two 10 cm culture dishes. Incubate at 37 °C for 4 h.

[0116] (11) Collect the supernatant and discard the adherent cells (the adherent cells should be tissue-resident macrophages). 4℃, 450g, 10min. Discard the supernatant and resuspend the cells in 10mL of RPMI 1640 complete medium (containing 10% FBS and antibiotics) containing 15% L929 cell supernatant (L929 supernatant: complete medium = 15:85, v / v).

[0117] (12) Add another 20 mL of culture medium containing 15% L929 cell supernatant. Seed 10 mL / plate into 10 cm plates. Incubate at 37°C for 7 days.

[0118] L929 cell supernatant: L929 cells were cultured in RPMI 1640 medium. On the second day after passage, the original medium was discarded, and non-adherent cells were washed away. 20 mL of RPMI 1640 complete medium was added, and the cells were cultured continuously for 7 days. After 7 days, the culture supernatant was aspirated and centrifuged at 600 g, 4°C for 10 min. The precipitate was discarded, and the supernatant was stored at -80°C for later use.

[0119] 3.2 Establishment of in vitro bone marrow-derived macrophages and the RAW264.7 macrophage line M1 polarization model

[0120] (1) 1 million primary mouse bone marrow-derived macrophages (BMDM) (or RAW264.7 macrophages) were seeded in 6-well plates and cultured in 1 mL of RPMI 1640 complete medium (or DMEM complete medium) until adherent.

[0121] (2) After starving the subjects for 12 hours with 1 mL of serum-free RPMI 1640 medium (or DMEM medium), the subjects were then stimulated with RPMI 1640 complete medium (or DMEM complete medium) containing 100 ng / mL LPS (LPS was prepared into a solution with a concentration of 100 μg / mL using sterile water) for 6 hours (for RNA extraction) and 12 hours (for protein extraction). The experimental groups were simultaneously incubated with drugs. AD or AO was dissolved in dimethyl sulfoxide (DMSO) to prepare stock solutions with concentrations of 25 mg / mL and 25 mmol / L, respectively, for administration. The control and model groups received the same volume of DMSO. All groups were incubated at 37°C, 90% relative humidity, and 5% (v / v) CO2.

[0122] (3) Remove the culture medium from the cells, wash the cells three times with PBS, add 1 mL of Trizol to each well for RNA extraction or add 50 μL of protein lysis buffer for protein extraction and Western blot.

[0123] 3.3 MTT Experiment

[0124] (1) Collect RAW264.7 cells in the logarithmic growth phase.

[0125] (2) Adjusting the concentration of the cell suspension: In a clean bench, clean the cell counting chamber and coverslip with alcohol. Take 20 μL of the cell suspension and inject it into the counting chamber using a pipette tip held against the center of one side of the coverslip. Under low magnification, count the cells in the four large squares at the four corners and calculate the average value. The cell concentration in the suspension is: average value × 10⁻⁶. 4(cells / mL). The number of cells seeded per well in a 96-well plate is 1 × 10⁻⁶. 4 Add 100 μL to each well and adjust the concentration of the cell suspension with complete culture medium.

[0126] (3) Grouping according to experimental requirements: zeroing group (excluding cells), control group, and drug administration group (with 6 parallel wells).

[0127] (4) Incubate the 96-well plates at 37°C (90% relative humidity, 5% CO2 concentration v / v) until the cells cover the bottom of the wells. After starving the cells in blank DMEM medium (without FBS) for 12 h, replace the medium with complete DMEM medium (containing 10% FBS v / v) containing 100 ng / mL LPS (LPS was prepared with sterile water to a stock solution with a concentration of 100 μg / mL for administration) and continue incubation for 12 h. At the same time, add drugs (AD or AO) at gradient concentrations to the treatment groups. AD or AO was prepared from DMSO to a concentration of 25 mg / mL and 25 mmol / L for administration.

[0128] (5) Terminate the culture, discard the culture medium, add 20 μL of 5.0 g / L tetramethylazobium bromide (MTT) solution to each well, and incubate for another 4 h in a cell culture incubator at 37 ℃.

[0129] (6) After 4 hours, aspirate the supernatant. Add 150 μL of DMSO to each well and place the plate in a microplate reader. Shake the plate for 10 minutes to completely dissolve the blue formazan crystals. Then measure the absorbance at 540 nm and calculate the cell viability using the following formula:

[0130] Cell viability = (Drug-treated group - Zero-adjustment group) / (Control group - Zero-adjustment group)

[0131] 3.4 The pharmacological effects of Kauri extract (AD) and monomeric AO on inhibiting RAW264.7 macrophage and BMDM M1 polarization, inflammatory factors, and oxidative stress.

[0132] RAW264.7 macrophages (or BMDM) were seeded in six-well plates at a density adjusted to 0.5 × 10⁻⁶ cells / well. 6RAW264.7 macrophages (or BMDM) were cultured at 10% FBS in DMEM (or RPMI 1640) until adherent, and then starved for 12 h in serum-free DMEM (or RPMI 1640). RAW264.7 macrophages (or BMDM) were cultured in complete DMEM (or RPMI 1640) (containing 10% FBS) containing 100 ng / mL LPS (LPS was prepared into a 100 μg / mL solution with sterile water for administration). The treatment groups were simultaneously incubated with 25 μg / mL Kauri extract AD or 25 μmol / L AO at 37°C, 90% relative humidity, and 5% CO2 v / v. Cells were collected after 6 h (for RNA extraction) and 12 h (for protein extraction) for the detection of M1 polarization markers, inflammation, and oxidative stress marker expression. Six parallel wells were used for each group. AD or AO was prepared from DMSO at concentrations of 25 mg / mL and 25 mmol / L, respectively, for administration.

[0133] 3.5 The pharmacological effects of Kauri extract (AD) on inhibiting RAW264.7 macrophages and BMDM glycolysis.

[0134] RAW264.7 macrophages (or BMDM) were seeded in six-well plates at a density adjusted to 0.5 × 10⁻⁶ cells / well. 6 RAW264.7 macrophages (or BMDM) were cultured in complete medium containing 10% FBS (DMEM for RAW264.7 cells and RPMI 1640 for BMDM cells) until adherent, and then starved for 12 h in serum-free DMEM (or RPMI 1640). RAW264.7 macrophages (or BMDM cells) were cultured in complete DMEM medium (or RPMI 1640 medium containing 10% FBS) containing 100 ng / mL LPS (LPS was prepared into a 100 μg / mL solution with sterile water for administration). The treatment groups were simultaneously given 25 μg / mL Kauri extract AD. Incubation was performed at 37°C, 90% relative humidity, and 5% CO2 v / v. After 6 h of culture, RNA was extracted to observe the expression of the key glycolysis gene HK2. After 12 h or 24 h of culture, the supernatant was collected to observe glucose consumption and lactate production. Six parallel wells were set up for each group. AD was prepared in DMSO at a concentration of 25 mg / mL for administration.

[0135] 4. Experimental Results and Discussion

[0136] 4.1 Kauri extract (AD) inhibits LPS-induced M1 polarization, inflammation, and oxidative stress in RAW 264.7 macrophages.

[0137] Cells were stimulated with 100 ng / mL LPS and simultaneously treated with 25 μg / mL AD. The results showed that AD significantly inhibited the LPS-induced increase in mRNA expression levels of inflammatory cytokines IL-6, MCP-1, and TNF-α; inhibited the increase in mRNA expression levels of M1 polarization markers CD80, CD86, and iNOS, and upregulated iNOS protein expression; AD inhibited the upregulation of caspase 1 and IL-18 protein expression; and AD inhibited the LPS-induced increase in ROS levels in cells (see...). Figure 1 ).

[0138] 4.2 Kauri extract (AD) inhibits LPS-induced M1 polarization and inflammatory factor expression in BMDM.

[0139] Cells were stimulated with 100 ng / mL LPS and treated with 25 μg / mL AD. The results showed that AD significantly inhibited the LPS-induced increase in the mRNA expression levels of inflammatory cytokines IL-6, MCP-1, TNF-α and IL-18; inhibited the increase in the mRNA expression levels of M1 polarization markers CD80, CD86 and iNOS and upregulated the protein expression of iNOS; flow cytometry analysis using PE-labeled CD86 antibody showed that AD significantly inhibited the LPS-induced expression of the M1 polarization marker CD86 in BMDM (see 2).

[0140] 4.3. Kauri extract (AD) inhibits glycolysis in RAW264.7 cells and regulates gene expression in glucose metabolism pathways.

[0141] Cells were stimulated with 100 ng / mL LPS and simultaneously treated with 25 μg / mL AD. The results showed that after 12 h or 24 h of culture, AD significantly inhibited the increase in LPS-induced cellular glycolysis, demonstrating inhibition of glucose consumption and lactic acid production. Simultaneously, AD significantly inhibited the upregulation of mRNA expression of HK2, a key enzyme in LPS-induced glycolysis (see...). Figure 3 ).

[0142] 4.4. Kauri extract (AD) inhibits glycolysis in BMDM cells and regulates gene expression in glucose metabolism pathways.

[0143] Cells were stimulated with 100 ng / mL LPS and simultaneously treated with 25 μg / mL AD. The results showed that after 12 h of culture, AD significantly inhibited the increase in LPS-induced cellular glycolysis, demonstrating a reduction in lactic acid production. Simultaneously, AD significantly inhibited the upregulation of mRNA expression of HK2, a key enzyme in LPS-induced glycolysis (see...). Figure 4 ).

[0144] 4.5. Kauri extract (AD) inhibits LPS-induced acute lung injury in mice with sepsis.

[0145] AD (100 mg / kg / day by gavage) significantly improved the survival rate of mice with high-dose (45 mg / kg) LPS-induced septicemia. AD (100 mg / kg / day by gavage) significantly reduced the increase in lung weight index in LPS (20 mg / kg)-induced septicemia mice; M1-polarized macrophage infiltration was observed in lung tissue, manifested by the inhibition of increased CD86 and CD80 mRNA expression levels; and the expression of inflammatory factors IL-6, TNF-α, IL-1β, and IL-18 in lung tissue was significantly inhibited, indicating that AD significantly suppressed inflammatory damage in lung tissue. HE staining results showed that AD significantly inhibited LPS-induced inflammatory cell infiltration and alveolar septal thickening in mouse lung tissue, indicating that AD significantly suppressed LPS-induced acute lung injury in LPS-induced septicemia mice (see...). Figure 5 ).

[0146] 4.6 Monomeric AO inhibits LPS-induced RAW 26 4.7 M1 polarization, inflammation, and oxidative stress in macrophages

[0147] Cells were stimulated with 100 ng / mL LPS and simultaneously treated with 25 μM AO or 25 μg / mL AD. The results showed that AO significantly inhibited the LPS-induced increase in mRNA expression levels of inflammatory cytokines MCP-1, IL-6, and TNF-α; inhibited the increase in mRNA expression levels of the M1 polarization marker iNOS; while 100 μM AO treatment significantly inhibited the expression of M1 polarization markers CD80 and CD86; AO inhibited the LPS-induced upregulation of the inflammatory cytokine IL-18 protein expression level and upregulated the LPS-induced decrease in the expression level of the antioxidant protein HO-1 (see...). Figure 6 ).

[0148] 4.7 Monomeric AO inhibits LPS-induced acute lung injury in mice with sepsis

[0149] AO (100 mg / kg / day, administered by gavage) significantly reduced the increase in lung weight index induced by LPS (20 mg / kg) in septic mice; reduced M1 polarized macrophage infiltration in lung tissue, manifested by inhibiting the increase in CD86 and CD80 mRNA expression levels; and significantly inhibited the mRNA expression levels of inflammatory factors IL-6, TNF-α, and IL-1β in lung tissue, indicating that AO significantly inhibited LPS-induced inflammatory damage in the lung tissue of septic mice. HE staining results showed that AO significantly inhibited inflammatory cell infiltration and alveolar septal thickening in the lung tissue of LPS-induced septic mice, indicating that AO significantly inhibited LPS-induced acute lung injury in septic mice (see...). Figure 7 ).

Claims

1. The use of Norfolk Island ketone in the preparation of drugs for the prevention and / or treatment of acute lung injury in sepsis; The structural formula of the arabinone is shown below: 。 2. Use according to claim 1, characterized in that: The aforementioned acute lung injury due to sepsis refers to acute lung injury caused by bacterial infection.

Citation Information

Patent Citations

  • Application of kaura fir extract in preparation of anti-non-alcoholic fatty liver product

    CN112933120A

  • Application of cowherb seed flavonoid glycoside in preparation of medicine for treating sepsis

    CN114748493A